Navigation Links
Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research

Collaboration with Lentigen Expands Research Applications for RNAi

WALTHAM, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has collaborated with Lentigen Corporation to develop a powerful new technology platform that expands applications for RNAi (RNA interference) to critical fields of life sciences research, including neuroscience, immunology and stem cell biology. This advancement, called Thermo Scientific Dharmacon(R) SMARTvector(TM) shRNA Lentiviral Particles, combines Thermo Scientific gene-silencing technologies with Lentigen's expertise in viral-delivery systems. SMARTvector will help researchers overcome common challenges faced when using RNAi, leading to permanent gene silencing in a wide range of cell types.

"With the SMARTvector advancement, we can now effectively deliver stably expressed gene silencing sequences into a broad range of cell types, including those that are difficult to work with, such as primary cells, non-dividing cells, stem cells and neuronal cell lines," said Dr. Ian Jardine, vice president of global research and development for Thermo Fisher Scientific. "Scientists using these cell lines can now harness the power of RNAi in their research, overcoming fundamental limitations in certain existing technologies."

Scientists at Thermo Fisher Scientific have applied innovations in RNAi to develop a novel, dedicated shRNA (short-hairpin RNA) design algorithm that is key to the SMARTvector platform. The algorithm uses criteria unique to shRNA- based silencing for the routine production of highly functional sequences specific to every gene in human, mouse and rat genomes.

"Thermo Fisher Scientific has developed a specialized shRNA design algorithm that greatly enhances the ability to select highly functional gene targeting sequences," added Jardine. "Alternative technologies frequently produce shRNA sequences that are ineffective at silencing the targeted genes, while causing high levels of unintended gene silencing that can lead to flawed experimental results."

By combining shRNA with Lentigen's proprietary viral vector delivery system, the gene silencing sequence is integrated into the host cell genome. This creates permanent gene silencing that cannot be achieved with synthetic siRNAs. Permanent gene silencing is crucial in many types of experiments, including those that examine complex gene networks in drug development and neurobiology.

Dr. Boro Dropulic, founder and chief executive officer of Lentigen, said, "By linking Lentigen's lentiviral technology and production capabilities with the RNAi expertise of Thermo Fisher Scientific, we are giving scientists a new tool that enables a much broader range of experiments involving gene silencing."

Thermo Scientific Dharmacon SMARTvector shRNA Lentiviral Particles can be ordered at .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit

Media Contact Information: Investor Contact Information:

Lori Gorski Ken Apicerno

Phone: 781-622-1242 Phone: 781-622-1111

E-mail: E-mail:


SOURCE Thermo Fisher Scientific Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
4. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
9. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
10. Inspire Announces Presentations at Two European Scientific Conferences
11. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
Post Your Comments:
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
Breaking Medicine News(10 mins):